Driehaus Capital Management Reduces $14M in Septerna, Inc. ($SEPN)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Driehaus Capital Management trimmed its position in Septerna, Inc. ($SEPN) by 8.61% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,395,572 shares of Septerna, Inc. after selling 413,898 shares during the quarter. Driehaus Capital Management's holdings in Septerna, Inc. were worth $150.06 million as of its most recent filing.
Septerna, Inc. Stock Down 12.3%
Shares of Septerna, Inc. ($SEPN) traded around $34.14 on Saturday, down 12.3% for the day.
Septerna, Inc. Earnings
Analysts Set New Price Targets
About Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Get Septerna, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SEPN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.